Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... LONDON , May 27, 2015  The ... provides comprehensive understanding and unprecedented access to the ... worlds leading healthcare companies during 2014. ... gain insight into the partnering activities of the ... view all the partnering and alliances deals announced ...
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) has ... Cancer Monoclonal Antibodies Market Outlook 2020" report ... to dominate the breast cancer monoclonal antibody segment ... Herceptin has been able to dominate this segment ... cancer cells become recalcitrant and relapsed condition could ...
(Date:5/27/2015)... , May 27, 2015 /CNW/ - CQDM, Brain Canada ... to $8.5M to six (6) multi-disciplinary and multi-provincial research ... within their Focus on Brain strategic initiative. To this ... involved as in-kind contributions. This exciting announcement was made ... for Neuroscience in the presence of Inez Jabalpurwala, President ...
(Date:5/27/2015)... Empowering biomedical researchers with richer, ... Inc. today announced its MR Compatible Small Animal ... Scanner uses silicon photomultiplier detector technology, so it ... from manufacturers like Bruker and Agilent,” said James ... “This enables simultaneous PET and MRI data acquisition ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10Cubresa Launches Simultaneous PET/MRI Technology 2
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... 2015  Technology is rapidly advancing, outpacing enterprises, ability ... cloud. Passwords and their management are soon to be ... specifications such as those developed by the FIDO Alliance™. ... presents for BYOD, COPE, IoT, and mobile payments, the ... In response to the call for ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... but treatable kind of addiction. However, not all people who ... stop taking drugs. A new study shows that, in the ... of craving, an antisocial personality type and previous heroin abuse ... into the habit. Ana Lpez, lead author of the ...
... on Skin of Amphibians May Protect Against Lethal Fungus ... bacteria on the skin of salamanders could help protect ... a lethal skin disease. The researchers from James ... report their findings in the November 2009 issue of ...
... stress in humans has been implicated in heart disease, weight ... Extreme environments, a source of chronic stress, present a ... exception. Yet, some species somehow manage to survive, and ... article by Dr. Yuri Springer in the November issue of ...
Cached Biology News:Why can't some people give up cocaine? 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4The benefits of stress ... in plants 2
... Polymerase is the most thoroughly characterized enzyme ... to its overall utility and efficacy. , ... for PCR applications. , It is ... ,, AmpliTaq DNA Polymerase is a 94 ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a ... advantages for all PCR applications. GCpro Taq ... clone expressed in E. coli, containing the ... The enzyme includes a highly processive 5'-3' ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: